Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 3/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.34 |
| ▸ | CASR | P41180 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5901843 | 0.87 | OPRK1 (0.41) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL5901991 | 0.82 | GUSB (0.40) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL5901828 | 0.82 | IMPDH2 (0.33) | HRH4IDO1 | |
| SCHEMBL5815326 | 0.70 | — | — | |
| SCHEMBL8728739 | 0.67 | DAO (0.41) | HRH4IDO1 | |
| SCHEMBL29777912 | 0.65 | LOXL2 (0.64) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL1442945 | 0.65 | LOXL2 (0.64) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL7169246 | 0.65 | LOXL2 (0.69) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL29403791 | 0.65 | LOXL2 (0.69) | LOXL2MTNR1AMTNR1BHRH3AHR | |
| SCHEMBL401081 | 0.65 | LOXL2 (0.69) | LOXL2MTNR1AMTNR1BHRH3AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060229355-A1 | 3.3'-Diindolylmethane compositions inhibit angiogenesis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229355-A1 | 3.3'-Diindolylmethane compositions inhibit angiogenesis | FLT4, FLT1, PGF | LOXL2 1121/4885MTNR1A 720/4885MTNR1B 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.